Supplementary figure 1.jpg (1.79 MB)
Download file

Supplementary Figure 1 - Engineered mesoporous silica reduces long-term blood glucose and HbA1c, and improve metabolic parameters in prediabetics

Download (1.79 MB)
figure
posted on 02.12.2021, 14:23 authored by Jeanha Baek, Ghislaine Robert-Nicoud, Carmen Herrera Hidalgo, Melissa L. Borg, Muhammad N. Iqbal, Roger Berlin, Maria Lindgren, Erik Waara, Anna Uddén, Kirsi Pietiläinen, Tore Bengtsson

Supplementary Figure 1. Effect of SiPore15® treatment during the entire 24-week clinical trial period: 12 weeks of treatment and 12 weeks of follow-up. Changes in the (a) HbA1c level, (b) body weight, (c) BMI, (d) total cholesterol level, (e) LDL cholesterol level, (f) SAD, (g) insulin level, (h) HOMA-IR were measured during the 12-week treatment period and continued to be measured 12 weeks after treatment had finished. The data were analyzed using the Wilcoxon signed rank test where the comparison was between the specific time point (week 6, 12, 18, 24) and the baseline. P values less than 0.05 were considered statistically significant and are shown above. All data are presented as mean + SEM (n=38 for All-participants group, n=27 at baseline and at week 6 and n=9 at week 12, 18, 24 for Conformant-batch group).

Funding

T Bengtsson is supported by the Vetenskapsradet Medicin (VR-M) from the Swedish Research Council. T Bengtsson owns stock in the following pharmaceutical companies: Sigrid Therapeutics AB, Atrogi AB and Glucox Biotechnology AB. The following authors are or were employed by Sigrid Therapeutics AB: J Baek, G Robert-Nicoud, C. Herrera Hidalgo, ML Borg, MN Iqbal, M Lindgren, ER Waara, A Uddén. T Bengtsson is one of the inventors of the patent family WO2014072363A1. T Bengtsson and MN Iqbal are inventors of the patent family WO2019166656A1.

History